{"id":8496,"date":"2024-09-06T11:13:25","date_gmt":"2024-09-06T04:13:25","guid":{"rendered":"https:\/\/thaipropertynews.com\/feeds\/?p=8496"},"modified":"2024-09-06T11:13:25","modified_gmt":"2024-09-06T04:13:25","slug":"sciwind-biosciences-announces-oral-presentations-at-the-european-association-for-the-study-of-diabetes-60th-annual-meeting-easd-2024","status":"publish","type":"post","link":"https:\/\/thaipropertynews.com\/feeds\/?p=8496","title":{"rendered":"Sciwind Biosciences Announces Oral Presentations at the European Association for the Study of Diabetes 60th Annual Meeting (EASD 2024)"},"content":{"rendered":"

HANGZHOU, China<\/span> and SAN FRANCISCO<\/span>, Sept. 6, 2024<\/span> \/PRNewswire\/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present positive results from a Phase 3 clinical study of injectable ecnoglutide (XW003) in patients with type II diabetes mellitus and from a Phase 1 study of oral ecnoglutide (XW004) in healthy and healthy obese participants, at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting, to be held in Madrid, Spain<\/span>, September 9<\/span> \u2013 13, 2024.\u00a0\u00a0<\/p>\n

Details of the oral presentations are as follows:<\/p>\n

Title: A Phase 3 Evaluation of cAMP Signaling Biased GLP-1 Analog Ecnoglutide (XW003) in Adults with Type 2 Diabetes (Presentation #148)<\/p>\n

Presenter: Susan Xu<\/span>, MD, PhD
Date\/Time: Sep 12, 2024<\/span>, 10:45 AM<\/span> \u2013 12:15 PM\u00a0CEST
Session: OP 25 (Incretin Receptor Agonists: Better and Better)<\/p>\n

Title: Phase 1 Topline Safety, Efficacy, and Pharmacokinetics of Oral Ecnoglutide (Presentation #736)<\/p>\n

Presenter: Mohammed Junaidi<\/span>, MD
Date\/Time: Sep 12, 2024<\/span>, 2:00 PM<\/span> \u2013 3:00 PM\u00a0CEST
Session: SO 060 (Novel Incretins: It is All about Clinical Outcomes)<\/p>\n

About Ecnoglutide\u00a0\u00a0<\/p>\n

Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for MASH.\u00a0 Ecnoglutide is a novel, cAMP signaling biased, long-acting glucagon-like peptide-1 (GLP-1) peptide optimized for improved biological activity and cost-effective manufacturing. \u00a0Ecnoglutide has demonstrated treatment benefits for patients with type 2 diabetes and people with overweight or obesity and is safe and well tolerated in Phase 1 through Phase 3 clinical studies.\u00a0<\/p>\n

About Sciwind Biosciences<\/p>\n

Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates, including the long-acting GLP-1 peptide analog XW003 (Phase 3), oral GLP-1 peptide analog XW004 (Phase 1), an oral small molecule GLP-1 receptor agonist XW014 (Phase 1), and novel amylin analogs (preclinical). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies. For more information, visit www.sciwindbio.com<\/a>.<\/p>\n

\u00a0<\/p>","protected":false},"excerpt":{"rendered":"

<\/p>\n

HANGZHOU, China<\/span> and SAN FRANCISCO<\/span>, Sept. 6, 2024<\/span> \/PRNewswire\/ — Sciwind Biosciences Co., Ltd., a clinical-stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease, today announced that the company will present positive results from a Phase 3 clinical study of injectable ecnoglutide (XW003) in patients with type II diabetes mellitus and from a Phase 1 study of oral ecnoglutide (XW004) in healthy and healthy obese participants, at the European Association for the Study of Diabetes (EASD) 60th Annual Meeting, to be held in Madrid, Spain<\/span>, September 9<\/span> \u2013 13, 2024.\u00a0\u00a0<\/p>\n

Details of the oral presentations are as follows:<\/p>\n

Title: A Phase 3 Evaluation of cAMP Signaling Biased GLP-1 Analog Ecnoglutide (XW003) in Adults with Type 2 Diabetes (Presentation #148)<\/p>\n

Presenter: Susan Xu<\/span>, MD, PhD
Date\/Time: Sep 12, 2024<\/span>, 10:45 AM<\/span> \u2013 12:15 PM\u00a0CEST
Session: OP 25 (Incretin Receptor Agonists: Better and Better)<\/p>\n

Title: Phase 1 Topline Safety, Efficacy, and Pharmacokinetics of Oral Ecnoglutide (Presentation #736)<\/p>\n

Presenter: Mohammed Junaidi<\/span>, MD
Date\/Time: Sep 12, 2024<\/span>, 2:00 PM<\/span> \u2013 3:00 PM\u00a0CEST
Session: SO 060 (Novel Incretins: It is All about Clinical Outcomes)<\/p>\n

About Ecnoglutide\u00a0\u00a0<\/p>\n

Glucagon-like peptide-1 (GLP-1) analogs are effective therapies in managing type 2 diabetes, obesity, and have demonstrated clinical potential as a treatment for MASH.\u00a0 Ecnoglutide is a novel, cAMP signaling biased, long-acting glucagon-like peptide-1 (GLP-1) peptide optimized for improved biological activity and cost-effective manufacturing. \u00a0Ecnoglutide has demonstrated treatment benefits for patients with type 2 diabetes and people with overweight or obesity and is safe and well tolerated in Phase 1 through Phase 3 clinical studies.\u00a0<\/p>\n

About Sciwind Biosciences<\/p>\n

Sciwind Biosciences is a clinical stage biopharmaceutical company focusing on discovering and developing innovative therapies to treat metabolic disease. Its product pipeline consists of potentially first-in-class and best-in-class drug candidates, including the long-acting GLP-1 peptide analog XW003 (Phase 3), oral GLP-1 peptide analog XW004 (Phase 1), an oral small molecule GLP-1 receptor agonist XW014 (Phase 1), and novel amylin analogs (preclinical). Sciwind has developed multiple proprietary technologies, including oral peptide and inhaled protein therapeutic delivery platforms and identified a series of drug candidates based on these core platform technologies. For more information, visit www.sciwindbio.com<\/a>.<\/p>\n

\u00a0<\/p>\n

<\/p>\n","protected":false},"author":0,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"rop_custom_images_group":[],"rop_custom_messages_group":[],"rop_publish_now":"initial","rop_publish_now_accounts":[],"rop_publish_now_history":[],"rop_publish_now_status":"pending","footnotes":""},"categories":[5,7],"tags":[],"class_list":["post-8496","post","type-post","status-publish","format-standard","hentry","category-cision-pr-newswire","category-cision-pr-newswire-en"],"_links":{"self":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/8496","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/types\/post"}],"replies":[{"embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=8496"}],"version-history":[{"count":0,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=\/wp\/v2\/posts\/8496\/revisions"}],"wp:attachment":[{"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=8496"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=8496"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/thaipropertynews.com\/feeds\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=8496"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}